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Background: The use of near-infrared (NIR) fluorescence imaging techniques has gained great interest for early
detection of cancer owing to the negligible absorption and autofluorescence of water and other intrinsic biomolecules
in this region. The main aim of the present study is to synthesize and characterize novel NIR fluorescent nanoparticles
based on proteinoid and PLLA for early detection of colon tumors.
Methods: The present study describes the synthesis of new proteinoid-PLLA copolymer and the preparation of NIR
fluorescent nanoparticles for use in diagnostic detection of colon cancer. These fluorescent nanoparticles were
prepared by a self-assembly process in the presence of the NIR dye indocyanine green (ICG), a FDA-approved NIR
fluorescent dye. Anti-carcinoembryonic antigen antibody (anti-CEA), a specific tumor targeting ligand, was covalently
conjugated to the P(EF-PLLA) nanoparticles through the surface carboxylate groups using the carbodiimide activation
method.
Results and discussion: The P(EF-PLLA) nanoparticles are stable in different conditions, no leakage of the
encapsulated dye into PBS containing 4% HSA was detected. The encapsulation of the NIR fluorescent dye within the P
(EF-PLLA) nanoparticles improves significantly the photostability of the dye. The fluorescent nanoparticles are non-toxic,
and the biodistribution study in a mouse model showed they evacuate from the body over 24 h. Specific colon tumor
detection in a chicken embryo model and a mouse model was demonstrated for anti-CEA-conjugated NIR fluorescent
P(EF-PLLA) nanoparticles.
Conclusions: The results of this study suggest a significant advantage of NIR fluorescence imaging using NIR
fluorescent P(EF-PLLA) nanoparticles over colonoscopy. In future work we plan to broaden this study by encapsulating
cancer drugs such as paclitaxel and/or doxorubicin, within these biodegradable NIR fluorescent P(EF-PLLA)
nanoparticles, for both detection and therapy of colon cancer.
Keywords: Proteinoid nanoparticles, Fluorescent nanoparticles, NIR fluorescence, Optical imaging, Colon cancerBackground
In recent years, several types of nanoparticles have been
introduced to the field of cancerous tissue detection.
When referring to colon cancer specifically, the early de-
tection of adenomatous colonic polyps is a major concern,
as the early detection is the key to survival [1,2]. Up until
now, colorectal cancer screening includes either stool-
based tests or endoscopic and radiological examination of
the colon [3,4]. These techniques are considered to be* Correspondence: shlomo.margel@mail.biu.ac.il
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article, unless otherwise stated.invasive and insensitive, causing poor patient compliance.
Thus, colon cancer continues to be a major cause of death.
As recently studied and published by several research
groups, novel near-infrared (NIR) fluorescent nanoparticles
may serve as a valuable tool in the field of colon tumor
detection [5,6]. The nanoparticles introduce the use of
fluorescence in the NIR region (700–1000 nm), where
autofluoresence, light scattering and absorption of the
light by normal tissues is not a concern. This way, the
imaging has an improved signal-to-noise ratio, as the
background is non-fluorescent in the NIR region and the
detection of the fluorophore is optimal [7-9]. Nanoparticlesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Characterization of the P(EF) and P(EF-PLLA)
polymers and particles
P(EF) P(EF-PLLA)f
Mw (kDa)a 165 168
Mn (kDa)a 138 156
PDIa 1.19 1.07
Optical activity [α]D
25°C (°)b −9.0 −4.5
Particle diameter (nm)c 196 ± 24 103 ± 11
Particle density (g/mL)d 0.001 0.005
aMolecular masses were measured by GPC, PDI is the polydispersity index,
given by Mw/Mn; bspecific optical rotation (c = 1, in H2O, at 25°C);
chydrodynamic particle diameter, measured by DLS, as described in the Materials
and methods section; dparticle density was measured as described in the Materials
and methods section; fP(EF-PLLA), PLLA 10% of the total monomer weight.
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proved to have significant advantages over free NIR dyes,
including biocompatibility, improved fluorescence signal,
enhanced photostability and the presence of functional
groups on the nanoparticle surface allowing easy conjuga-
tion to bioactive molecules [6,10-12]. Among various NIR
fluorescent dyes, cyanine dyes are already approved and
used in a wide range of biological applications, since they
are known as water-soluble, stable, sensitive and have sharp
fluorescence bands [13].
Recently, proteinoid particles were studied by several
groups as new drug delivery systems [14-16]. The thermal
condensation of amino acids into proteinoids was first de-
scribed and characterized by Fox and Harada [17-20].
When proteinoids are incubated in an aqueous solution
they form hollow particles that range in size according to
the environment conditions [21]. Since proteinoid parti-
cles are considered biodegradable, non-immunogenic and
non-toxic, they can be used as a delivery vehicle in the
body [16]. In this work, a new version of proteinoid is
synthesized and studied. In order to synthesize suitable
particles for this application, proteinoids made of nat-
ural amino acids along with low molecular weight poly
(L-lactic acid) (PLLA) were synthesized. The natural
amino acids L-glutamic acid (E) and L-phenylalanine (F)
are thermally polymerized with and without 2000 Da
PLLA. All of the monomers used are safe, without excep-
tion, as PLLA is widely used in many biomedical applica-
tions as medical implants, such as screws, pins, sutures,
rods [22,23], etc.
After preparation, the crude proteinoids can go through a
self-assembly process to form micro- and nano-sized parti-
cles [24,25]. If a molecule of a dye or a drug is introduced
during the self-assembly, the process may include the en-
capsulation of the molecule within the proteinoid particle
[16]. Here, indocyanine green (ICG), a well-known fluores-
cent cyanine dye, was encapsulated by the proteinoid-PLLA
to form new NIR fluorescent proteinoid-PLLA nanoparti-
cles. Leakage of the entrapped NIR dye into PBS in the ab-
sence and the presence of 4% albumin was not detected.
The NIR fluorescent P(EF-PLLA) nanoparticles, con-
taining ICG, were tested for their in vivo biodistribution
in a mouse model. Additionally, the NIR fluorescent P
(EF-PLLA) nanoparticles were conjugated to a bioactive
targeting molecule: anti-cacinoembryonic antigen anti-
bodies (anti-CEA) [12]. The bioactive-conjugated NIR
fluorescent P(EF-PLLA) nanoparticles were found to
specifically detect colon cancer tumors, as demonstrated
in tumor implants in a chicken embryo model and in a
mouse model.
Results and discussion
In the first stage of this study P(EF) and P(EF-PLLA) poly-
mers and particles have been prepared and characterizedas described in the Materials and methods section. Table 1
compares the physical and chemical properties of the
formed polymers and particles.
The incorporation of low molecular weight PLLA seg-
ments (2000 Da) in the copolymer backbone contributes
to the overall polymer biodegradability and the smaller
nanometric-scale size of the particles made of it. Fur-
thermore, it does not affect significantly the molecular
weights, improves slightly the polydispersity and de-
creases significantly the size and size distribution of the
obtained nanoparticles from 196 ± 24 to 103 ± 11 nm.
Additionally, the presence of the PLLA segments pro-
vides an additional safe way for biodegradation through
ester hydrolysis [22]. Hence, P(EF-PLLA) was selected as
the better polymer for this specific application.
Several P(EF-PLLA) copolymers were synthesized, chan-
ging the PLLA percentage in the total monomer weight,
as specified in the Materials and methods section. Figure 1
exhibits the effect of changing the PLLA content on the
different P(EF-PLLA) particle sizes.
As shown, the optimal particles, judging by their size
and size distribution, are the particles made of P(EF-PLLA)
where PLLA is 10% of the total monomer. In this case, the
particles formed are nanoparticles of the smallest nano-
metric size with a narrow size distribution, 103 ± 11 nm.
When PLLA is of lower percentage in the total monomer
weight, the copolymers self-assemble into larger particles
in size, 232–502 nm. Overall, as the PLLA fraction in the
copolymer rises, the particles formed are smaller in size,
indicating the importance of incorporating PLLA into the
proteinoid particles, where these hydrophobic moieties
are well-packed to form the interior of the nanoparticle.
However, P(EF-PLLA) with 20% PLLA does not self-
assemble into particles at the specified conditions in the
Materials and methods section.
The P(EF-PLLA) nanoparticle density measured as de-
scribed in the method section was 0.005 g/mL, indicating
that the particles formed have a relatively high volume
and a very low mass, probably hollow particles, as already
Figure 1 Effect of the PLLA weight% of the total monomer weight in synthesized P(EF-PLLA) on the hydrodynamic particle diameter.
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ture [26]. This is significantly important, since hollow par-
ticles may be used for the encapsulation of drugs and
dyes, etc.
The optimal P(EF-PLLA) nanoparticles were used to en-
capsulate ICG. Figures 2A and 2B show that the dry (A)
and hydrodynamic (B) diameters of the NIR fluorescent P
(EF-PLLA) nanoparticles are 70 ± 15 nm and 145 ± 20 nm,
respectively. The difference in diameters is due to the fact
that the hydrodynamic diameter takes into account the
water molecules around and within the hydrophilic nano-
particles. Figures 2C and 2D exhibit the fluorescence and
absorbance spectra of the NIR fluorescent P(EF-PLLA)
nanoparticles compared to those of the free dye in solu-
tion. The absorbance spectra shows no shift in the absorb-
ance, but a change in the maximal absorbance peak from
779 nm in free ICG to 718 nm in ICG-containing nano-
particles, probably since the ICG molecules get close to
each other inside the nanoparticle interior and aggregation
may occur and cause this change in absorbance [27,28].
Moreover, a blue-shift of 12 nm in the emission spectrum
of the NIR fluorescent nanoparticles compared to the free
ICG in solution was also observed, probably due to the
dye molecule aggregation inside the particle.
Leakage of the encapsulated ICG into PBS not-containing
and containing 4% albumin at room temperature was not
observed, indicating that the dye is strongly associated
within the P(EF-PLLA) nanoparticles, probably due to
physical interactions between the dye and the polymer.
Optimization of the ICG concentration encapsulated
within the P(EF-PLLA) nanoparticles
In order to optimize the ICG-containing P(EF-PLLA)
nanoparticles fluorescence intensity, different concentration(0.5-5% w/w relative to P(EF-PLLA)) of ICG were encap-
sulated in the P(EF-PLLA) nanoparticles, as described in
the Materials and methods section. The concentration of
encapsulated ICG that provided the maximum fluores-
cence intensity of the resultant NIR fluorescent P(EF-
PLLA) nanoparticles was 1% w/w relative to P(EF-PLLA).
At higher dye concentrations, fluorescence quenching was
observed, as the distance between the dye molecules en-
capsulated within the nanoparticle is shorter, resulting in
non-emissive energy transfer between them.
Photobleaching of the NIR fluorescent P(EF-PLLA)
nanoparticles
Photostability experiments of the free and the encapsu-
lated dye within the P(EF-PLLA) nanoparticles were per-
formed. Samples were illuminated at 800 nm and the
fluorescence intensities over 20 minutes of illumination
were recorded. Figure 3 shows that the fluorescence in-
tensity of free ICG in solution is decreased significantly
with time, as opposed to the fluorescence intensity of
the encapsulated ICG in the nanparticles, which remains
intact. The encapsulation of the dye protects the dye
from reactive oxygen species, other oxidizing or redu-
cing agents, temperature, exposure time and illumin-
ation levels, which may reduce the fluorescence intensity
irreversibly [5,10].
Nanoparticle stability
Long-term refrigeration of particle dispersions and freeze-
drying of particles are common ways to store nanoparti-
cles for long-time periods. P(EF-PLLA) nanoparticle were
kept in these conditions as mentioned in the Materials
and methods section, in order to determine their stability.
The nanoparticles were kept in refrigeration for 6 months
Figure 2 Characterization of the NIR fluorescent P(EF-PLLA) nanoparticles. (A, B) SEM image and hydrodynamic size histogram of the NIR
fluorescent P(EF-PLLA) nanoparticles; (C, D) emission and absorbance spectra of free ICG (dotted lines) and nanoparticles containing ICG
(solid lines), respectively.
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their size and size distribution over this period of time.
Additionally, no free ICG or soluble P(EF-PLLA) were de-
tected in the aqueous phase, and the fluorescence inten-
sity of the dispersion remained unaltered. These results
indicate that the NIR fluorescent nanoparticles may be
kept for long periods of time under refrigeration. The NIRfluorescent nanoparticles were also lyophilized to dryness
and then redispersed in an aqueous phase to their original
concentration. Yet again, the particles size, size distribution
and their fluorescence were not affected. This indicates
that the nanoparticles may be stored and handled as a
freeze-dried powder and redispersed upon use without the
addition of cryoprotectants prior to drying, as common to
Figure 3 Photostability of the ICG-containing P(EF-PLLA) particles (A) and free ICG (B) as function of time. Samples of ICG-containing P
(EF-PLLA) particles and free ICG were illuminated with a Xenon flash lamp for 20 min as described in the Materials and methods section.
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nanoparticles [29].
The stability of the fluorescent P(EF-PLLA) nanoparticles
as function of pH was tudied by ζ-potential measurements.
Figure 4 illustrates the ζ-potential curve of the nanoparti-
cles aqueous dispersion as function of pH. As presented
in the figure, there is a decrease in the ζ-potential of the
particles as the pH of the particle aqueous dispersions
increases: when pH was increased from 1.3 to 10.1, the
ζ-potential decreased from 3.0 to −34.7 mV. The isoelec-
tric point of the P(EF-PLLA) nanoparticles is around
pH 2, probably due to the large amount of negative chargeFigure 4 ζ-potential of the NIR fluorescent P(EF-PLLA) nanoparticles acarboxylate groups that self-assemble on the surface of
the nanoparticles.
In vitro cytotoxicity of the P(EF-PLLA) nanoparticles
In order to revoke cell toxicity of the NIR P(EF-PLLA)
nanoparticles, in vitro cytotoxicity of the particles was
tested by using human colorectal adenocarcinoma LS174t,
SW480 and HT29 cell lines. Cell cytotoxicity was assessed
by measuring the release of cytoplasmic lactate dehydro-
genase (LDH) into cell culture supernatants. LDH is an
intracellular enzyme which catalyzes the reversible oxida-
tion of lactate to pyruvate. Since LDH is predominantly ins function of pH.
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only upon cell damage or lysis [30]. Figure 5 exhibits the
cytotoxicity levels of the P(EF-PLLA) particles at two dif-
ferent concentrations (1.25 and 2.5 mg/mL). It can be seen
that at both concentrations, the P(EF-PLLA) particles have
no significant cytotoxic effect on all three cell lines, com-
pared to untreated cells, meaning that the nanoparticles
may be used for biomedical applications as suggested,
including drug delivery.
In vivo biodistribution in a mouse model
NIR fluorescent P(EF-PLLA) nanoparticles (2 mg/mL,
0.01 mg/kg body weight per mouse) were injected i.v.
into mice through the tail vein and checked at several
time intervals over 24 h. Figure 6 shows whole body im-
ages of mice injected with the nanoparticles over time:
at 5 min, 20 min, 1 h and 24 h from injection. 5 min
post injection, there is an initial burst of fluorescence
which subsided quickly, while the majority of the fluor-
escent nanoparticles concentrated in the liver, at 20 min.
24 h post injection, the fluorescence is almost non-
existent, signifying the nanoparticle clearance from the
body over 24 h. Biodistribution was tested for free ICG
as well, and no significant differences in distribution and
kinetics were found between nanoparticles containing
ICG and free ICG up to 24 h post injection. These find-
ings were in complete agreement with previous reports
of ICG and ICG-containing nanoparticles pharmacokinet-
ics and biodistribution, as the free dye in solution, deriva-
tives of the free dye and ICG-containing nanoparticles are
all evacuated from the body after 1 h and completely van-
ished 24 h after i.v. injection [31,32].Figure 5 Cytotoxic effect of the NIR fluorescent P(EF-PLLA) nanoparti
HT29 cell lines measured by the LDH assay. Cells (3 × 105) were incubat
2.5 mg/mL in PBS). Cells were incubated with 1% Triton-x-100 as positive co
and the P(EF-PLLA) nanoparticles (2.5 mg/mL) to revoke any interaction o
(negative control) were similarly incubated. Each bar represents mean ± stEx vivo fluorescence images of specific organs and blood
were also obtained. Organs from mice were harvested and
blood was drawn 5 min, 20 min, 1 h and 24 h post injec-
tion of the nanoparticles into the tail vein. Figure 7 shows
the calculated fluorescence intensities of the lungs, bones,
brain, colon, duodenum, heart, liver, kidney, spleen and
blood screening. Evidently, this analysis shows that the
nanoparticles penetrated and were found in all checked
organs. It is shown clearly that by 20 min most of the
inserted quantity of the fluorescenct nanoparticles is
cleared from the blood. The nanoparticles concentrate
mostly at the liver and are probably evacuated from the
body. Interestingly, it is also apparent that the nanoparti-
cles pass the blood–brain barrier (BBB), since they are
found in the brain at 20 min post injection. This may open
up a scope of drug targeting to the brain for drug mol-
ecules which are usually blocked. Overall, it was dem-
onstrated that following a single i.v. injection of the
nanoparticles, fluorescence intensity at all organs de-
creased over time, and only traces of fluorescence
could be seen after 24 h.
In vivo optical detection of human colon tumors on a
CAM model
To demonstrate the feasibility of using the NIR fluores-
cent P(EF-PLLA) nanoparticles for the detection of
colon tumors, monocloneal antibodies against CEA
(anti-CEA) and anti-rabbit IgG were conjugated to the
nanoparticles. Carcinoembryonic antigen, CEA, is a
highly glycosylated glycoprotein expressed in most hu-
man carcinomas, and therefore is used as an effective
biomarker in several modalities of human carcinoma. Ascles on human colorectal adenocarcinoma LS174t, SW480 and
ed for 24 and 48 h with the P(EF-PLLA) nanoparticles (1.25 and
ntrol (100% toxicity). In addition, cells were incubated with Triton-x-100 1%
f the nanoparticles with the LDH kit components. Untreated cells
andard deviations of 4 separate samples.
Figure 6 Typical whole body fluorescence images of the NIR fluorescent P(EF-PLLA) nanoparticles at 5 min (A), 20 min (B), 1 h (C) and
24 h (D) after i.v injection.12 mice (each experiment group contained 3 mice) were anesthetized and treated with NIR fluorescent P(EF-PLLA)
nanparticles (2 mg/mL, 0.01 mg/kg body weight per mouse). Blood was drawn and organs were harvested at each time point. 2 uninjected mice
served as negative control. 12 mice were injected correspondingly with free ICG solution, giving similar results (not shown). The experiment was
repeated twice with similar results.
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cosal side of the LS174t colorectal cancer cell line, as op-
posed to SW480 (at least x103 less) [33]. Anti-rabbit IgG
was conjugated to nanoparticles as a non-specific bind-
ing agent, with the intention of inactivating the conju-
gated particles in terms of tumor detection. As clearly
illustrated in Figure 8, LS174t tumors treated with anti-
CEA-conjugated nanoparticles (B) gained greater fluor-
escence compared to those treated with non-conjugated
nanoparticles (A) or anti-rabbit IgG-conjugated nano-
particles (C). This can be explained by the effective
ligand-receptor interaction. Furthermore, the SW480
tumors treated with the anti-CEA-conjugated nanopar-
ticles gained less fluorescence (about 3.5 times) com-
pared to the LS174t tumors treated the same way. The
fluorescent signal of LS174t tumors labeled by anti-
CEA-conjugated nanoparticles was 4 times higher thanFigure 7 Fluorescence intensities of different organs taken at 5 min,
mice (each experiment group contained 3 mice) were anesthetized and tre
0.01 mg/kg body weight per mouse). Blood was drawn and organs were h
control. The experiment was repeated twice with similar results.that of the the tumors labeled by the anti-rabbit IgG-
conjugated nanoparticles. Anti-rabbit IgG “blocks” the
particle from interacting with the tumor receptors by
the conjugation to the surface active moieties, thus serv-
ing as a negative control in colon tumor labeling. The
results discussed and calculated are an average of 3 dif-
ferent experiments, wherein each experiment contained
6 eggs in a group, altogether 18 eggs in each group.
In vivo optical detection of human colon tumors in a
mouse model
Labeling of human colorectal tumors was performed using
orthotopic mouse model (22 mice) with colonic tumors
originated from LS174t cells injected to the colon wall
2 weeks before the experiment. Mice were anesthetized
and treated with 0.1% bioconjugated NIR fluorescent P
(EF-PLLA) nanoparticles dispersion in PBS through the20 min, 1 h and 24 h post i.v. injection into mice tail veins. 12
ated with NIR fluorescent P(EF-PLLA) nanoparticles (2 mg/mL,
arvested at each time point. 2 uninjected mice served as negative
Figure 8 Fluorescent and grayscale images from a typical experiment of LS174t and SW480 human tumor cell lines implanted on
chicken embryo CAM treated with the non-conjugated (A), anti-CEA-conjugated (B) and anti-rabbit IgG-conjugated (C) NIR fluorescent
P(EF-PLLA) nanoparticles. Images of untreated tumors are shown in (D). The experiment was repeated 3 times with similar results.
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with PBS and were left to recover for 4 h. The colons were
then removed and prepared for the imaging as described
in the Materials and methods section. Figure 9 shows
typical (8 out of 10 mice) fluorescent and grayscale images
of the mice colons after treatment with anti- CEA (A) and
anti-rabbit IgG (B) conjugated nanoparticles. As illus-
trated in Figure 9A, the anti-CEA-conjugated nanoparti-
cles detected the tumors specifically and selectively with
good signal to background ratio (SBR), the background
refers to the surrounding non-pathological tissue. More-
over, as illustrated in Figure 9B, the “inactive” anti-rabbit
IgG-conjugated nanoparticles did not produce a signifi-
cant signal of the tumors.
Conclusions
Proteinoid and proteinoid-PLLA copolymer were made
from (L) glutamic acid, (L) phenylalanine and poly(L-lac-
tic acid) (2 kDa). The optimal copolymer P(EF-PLLA)
(10% PLLA), was used to encapsulate ICG to yield NIRFigure 9 Fluorescent and grayscale images of typical LS174t colon tu
NIR fluorescent P(EF-PLLA) nanoparticles. 20 mice (10 in each experime
in PBS, as described in the Materials and methods section. 2 untreated micfluorescent P(EF-PLLA) nanoparticles. The new NIR
fluorescent nanoparticles discussed in the work have the
potential to assist in early diagnosis of colonic neoplasms.
They are stable, avoiding leakage and photobleaching of
the dye over time and non-toxic. The nanoparticles pene-
trate a variety of organs, including the brain and bones,
and are evacuated almost completely over 24 h. The anti-
CEA-conjugated NIR fluorescent nanoparticles may be
very useful for tumor diagnosis in vivo, as they specifically
label LS174t colon tumors in the chicken embryo model
and in mice.
In future work, we plan to extend the study to include
other in vivo tumor detection devices, such as whole body
imaging or a fluorescent endoscopy camera. Additionally,
other tumor-targeting ligands, including antibodies, peptides
and proteins (TRAIL and EGF) [34,35] may be conjugated
to the nanoparticles. We also plan to encapsulate anti-
cancer drugs such as doxorubicin and/or paclitaxel within
the NIR fluorescent P(EF-PLLA) nanoparticles, providing
a strategy for both diagnosis and therapy of colon cancer.mors treated with anti-CEA (A) and anti-rabbit IgG (B) -conjugated
nt group) were anesthetized and treated with 0.1% particle dispersion
e served as a control group.
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Materials
The following analytical-grade chemicals were purchased
from commercial sources and were used without further
purification: L-glutamic acid (E), L-phenylalanine (F), indio-
cyaninegreen (ICG), human serum albumin (HSA), bovine
plasma fibrinogen, 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC), Matrigel, Triton-x-100 and monoclo-
nal anti-CEA antibodies (T86-66) from Sigma (Rehovot,
Israel); Poly(L-lactic acid) MW 2,000 Da from Polysciences
(Warrington, PA, USA); N-hydroxysulfosuccinimide
(Sulfo-NHS) and 2-morpholino ethanesulfonic acid
(MES, pH 6) from Thermo Fisher Scientific (Rockford,
IL, USA); Phosphate Buffered Saline (PBS), Minimum
Essential Medium (MEM) eagle, McCoy’s 5A medium
and Dulbecco’s modification of eagle’s medium (DMEM),
Fetal Bovine Serum (FBS), glutamine, penicillin, strepto-
mycin and mycoplasma detection kit from Biological
Industries (Bet Haemek, Israel); cell cytotoxicity assay kit
(LDH) from Roche (Switzerland); LS174t, SW480 and
HT29 cell lines from American Type Culture Collection
(ATCC); donkey anti-rabbit IgG from Jackson Immuno-
Research Laboratories (West Grove, PA, USA); water was
purified by passing deionized water through an Elga-
stat Spectrum reverse osmosis system (Elga Ltd., High
Wycombe, UK).
Synthesis and characterization of the P(EF) and
P(EF-PLLA) proteinoids
L-glutamic acid (E) was heated at 180°C in an oil bath,
under nitrogen atmosphere until melting. The liquefied
mass was stirred at 180°C for 30 min. To this, L- phenyl-
alanine (F) and poly(L-lactic acid) (PLLA, Mw= 2000 Da)
were added, and kept at 180°C under nitrogen. The total
monomer weight was 5 g, PLLA was added at different
percentages (1-20% of the total monomer weight) or not
added at all. The mixture was mechanically stirred at
150 rpm for 3 h. The product is a highly viscous orange-
brown paste, which hardens to give a glassy mass when
cooled to room temperature. Then, water (10 mL) was
added to the crude product, and the mixture was stirred
for 20 min. The solution was then intensively dialyzed
through a cellulose membrane (3500 Da MWCO) against
distilled water. The content of the dialysis tube was then
lyophilized to obtain a yellow-white powder.
The molecular weights and polydispersity indices of
the dried P(EF) and P(EF-PLLA) were determined using
Gel Permeation Chromatography (GPC) consisting of a
Waters Spectra Series P100 isocratic HPLC pump with
an ERMA ERC-7510 refractive index detector and a
Rheodyne (Coatati, CA) injection valve with a 20 μL
loop (Waters, MA). The samples were eluted with
super-pure HPLC water through a linear BioSep SEC-
s3000 column (Phenomenex) at a flow rate of 1 mL/min.The molecular weight was determined relative to poly
(ethylene glycol) standards (Polymer Standards Service-
USA, Silver Spring, MD) with a molecular weight range
of 100–450000 Da, Human Serum Albumin (HSA, 67 kDA)
and bovine plasma fibrinogen (340 kDa), using Clarity
chromatography software. The optical activities of the P
(EF-PLLA) and P(EF) were determined using a PE 343
polarimeter (PerkinElmer). The measurements were done
in water, at 589 nm at 25°C.Synthesis of the non-fluorescent and NIR fluorescent
P(EF) and P(EF-PLLA) nanoparticles
The P(EF) and P(EF-PLLA) nanoparticles were prepared
by a self-assembly process [21]. Briefly, 100 mg of the
dried fabricated P(EF) or P(EF-PLLA) were resuspended
in 10 mL of 10−5 N NaCl solution. The mixture was then
heated to 80°C while stirring for 15 min. The mixture was
removed from the hot plate and was allowed to return to
room temperature. During the cooling process, particles
formed and precipitated from the aqueous solution. The
formed nanoparticles were then dialyzed versus 4 L of
10−5 NaCl solution overnight at room temperature.
NIR fluorescent particles P(EF-PLLA) nanoparticles were
prepared by the same procedure, with the addition of ICG
(1 mg, 1% of the copolymer) to the hot solution, prior to
particle formation.Characterization of the non-fluorescent and NIR
fluorescent P(EF) and P(EF-PLLA) nanoparticles
Particle size and size distribution were determined using
DLS with photon cross-correlation spectroscopy (Nano-
phox particle analyzer, Sympatec GmbH, Germany) and
by Scanning Electron Microscopy (SEM, JOEL, JSM840
Model, Japan). In SEM samples, the diameters of more
than 200 particles were measured with AnalySIS Auto
image analysis software (Soft Imaging System GmbH,
Germany). The density of the particles was determined
by pycnometry. Briefly, dry pre-weighed particles were
put in a calibrated pycnometer, which was then filled
with water. The density of the particles was calculated
from the known density of the water, the weight of the
pycnometer filled only with water, the weight of the pyc-
nometer containing both the sample and water, and the
weight of the sample, as described in the literature [36].
Absorbance spectra were obtained using a Cary 100 UV-
Visible spectrophotometer (Agilent Technologies Inc.).
Excitation and emission spectra were recorded using a
Cary Eclipse spectrofluorometer (Agilent Technologies
Inc.). ζ-potential measurements were performed by
gradual titration of the nanoparticles’ aqueous dispersion
at pH range from 11 to 2.5 using 1 M HCl (Zetasizer zeta
potential analyzer 3000 Has Model, Malvern Instruments,
England).
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concentration in the NIR fluorescent P(EF-PLLA)
nanoparticles
The encapsulated ICG concentration was determined for
1 mg/mL nanoparticles, using a calibration curve of the
integrals of absorbance peaks of standard free ICG solu-
tions in PBS at 630–900 nm.
Different ICG quantities were encapsulated within the
P(EF-PLLA) nanoparticles at weight% ratios of 0.5, 1, 2,
and 5% relative to the P(EF-PLLA). The nanoparticle
dispersions were diluted to 1 mg/mL in PBS and their
fluorescence intensities at 809 nm were measured.
Leakage extent of the encapsulated ICG from the
nanoparticles dispersed in PBS containing 4% HSA
NIR fluorescent P(EF-PLLA) nanoparticles dispersions
(1 mg/mL in PBS containing 4% HSA) was shaken at 37°C
for 24 h and then filtered via a 300-kDa filtration tube
(VS0241 VIVA SPIN) at 4000 rpm (Centrifuge CN-2200
MRC). The fluorescence intensity of the supernatant was
then measured at 809 nm.
Photostability of the NIR fluorescent P(EF-PLLA)
nanoparticles
The photostability of the NIR fluorescenet P(EF-PLLA)
nanoparticles was examined by recording the fluores-
cence intensity over a period of 20 min of nanoparticle
dispersion in PBS and a PBS solution of free ICG (0.05 M).
The nanoparticle dispersion was diluted to give comparable
fluorescence intensity to the ICG solution, with λex set
at 780 nm and λem set at 800 nm. The excitation and
emission slits were opened to 20 nm and 5 nm, respect-
ively. Each of the samples was illuminated continuously
with a xenon lamp, and the fluorescence intensity was
recorded using a Cary Eclipse fluorescence spectropho-
tometer (Agilent Technologies Inc.). Intensity values were
normalized for comparison.
Particle stability in storage conditions
NIR fluorescent P(EF-PLLA) nanoparticles aqueous dis-
persions (1 mg/mL) were put in a refrigerator at 4°C for
6 months. Samples were taken at different time periods,
filtered through a centrifugation tube (Vivaspin 3000 Da
MWCO) and the filtrate was checked by UV at 200–
210 nm, to find soluble P(EF-PLLA) and at 630–900 nm
to find free ICG. The nanoparticle size, size distribution
and fluorescence were checked as well by the same pro-
cedures mentioned above.
Additionally, the nanoparticles were freeze-dried in order
to check their stability after drying. Following lyophilization,
the nanoparticles were resuspended in PBS to their original
concentration and the dispersions were retested for particle
size, size distribution and fluorescence intensity.In vitro cytotoxicity of the NIR fluorescent P(EF-PLLA)
nanoparticles
In vitro cytotoxicity of the P(EF-PLLA) nanoparticles was
tested by using human colorectal adenocarcinoma LS174t,
SW480 and HT29 cell lines. The cell lines are adherent to
the used culture dishes. LS174t cells were grown in Mini-
mum Essential Medium (MEM) eagle supplemented with
heat-inactivated fetal bovine serum (FBS, 10%), penicillin
(100 IU/mL), streptomycin (100 μg/mL) and L-glutamine
(2 mM). SW480 cells were maintained in Dulbecco’s
MEM supplemented with heat-inactivated fetal bovine
serum (FBS, 10%), penicillin (100 IU/mL), streptomycin
(100 μg/mL) and L-glutamine (2 mM). HT29 cells were
maintained in McCoy’s 5A medium supplemented with
FBS (10%), penicillin (100 IU/mL), streptomycin (100 μg/mL)
and L-glutamine (2 mM). Cells were screened to ensure
they remained mycoplasma-free using Mycoplasma
Detection Kit [37].
Cell cytotoxicity was assessed by measuring the release
of cytoplasmic lactate dehydrogenase (LDH) into cell cul-
ture supernatants. LDH activity was assayed using the
Cytotoxicity Detection Kit according to the manufacturer’s
instructions [30]. Cells (3 × 105 cells per well) were seeded
and grown to 90–95% confluency in 24 well plates before
treatment with the P(EF-PLLA) nanoparticles. Cell cul-
tures that were not exposed to the nanoparticles were in-
cluded in all assays as negative controls. Cell cultures that
were treated with 1% Triton-x-100 were used as positive
controls. To test if the nanoparticles can interact with
LDH kit compounds, cell cultures were exposed to a
mixture containing maximal nanoparticles concentration
(2.5 mg/mL) dispersed in PBS and 1% Triton-x-100.
The P(EF-PLLA) nanoparticles were freshly dispersed
in PBS (1.25 and 2.5 mg/mL) and then added to the 95%
confluent cell culture in culture medium. The cell cul-
tures were further incubated at 37°C in a humidified 5%
CO2 incubator and then checked for cellular cytotoxicity
at intervals of 24 h. The percentage of cell cytotoxicity
was calculated using the formula shown in the manufac-
turer’s protocol [30]. All samples were tested in tetraplicates.
Biodistribution in a mouse model
Male BALB/C mice (Harlan Laboratories, Israel) were uti-
lized in this study under a protocol approved by the Insti-
tutional Animal Care and Use Committee at Bar-Ilan
University. The biodistribution of the NIR fluorescent P
(EF-PLLA) nanoparticles was studied in normal 8-weeks-
old mice, weighing 20–25 g at the time of experiment.
Prior to the experiment, mice were anesthetized by intra-
peritoneal injection of Ketamine (40–80 mg/kg body
weight) and Xylazine (5–10 mg/kg body weight), and the
mice’s skin was shaved with an electric animal clipper.
100 μL of either nanoparticle dispersion or free ICG
solution (0.01 mg/kg body weight, dissolved in PBS)
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at a concentration of 2 mg/mL. During image acquisi-
tion, mice remained anesthetized by the intraperitoneal
injection of Ketamine/Xylazine. Image cubes were ob-
tained from the mice at several time points up to 24 h
after injection. Each treatment group includes 3 mice for
each time point (5 min, 20 min, 1 h and 24 h); 2 unin-
jected mice served as negative control. The experiment
was repeated twice, testing a total of 52 mice. At the end
of the experiment, the mice were euthanized by cervical
dislocation, and organs were taken for imaging (liver,
spleen, kidney, duodenum, colon, brain, heart, tibia bone
and blood).
Whole body fluorescence images were acquired using a
Maestro II in vivo fluorescence imaging system (Cambridge
Research &Instrumentation, Inc., Woburn, MA). The
system is equipped with a fiber-delivered 300 W xenon
excitation lamp, and images can be acquired from λ = 500-
950 nm by a 1.3 megapixel CCD camera (Sony ICX285
CCD chip). Each pixel within the image cube therefore
has an associated fluorescence spectrum. The software for
the Maestro system (Maestro 2.10.0) contains several algo-
rithms to process the spectral data cubes to remove un-
desired auto-fluorescence signal and generate overlaid
images for multiple fluorophores. A deep red excitation/
emission filter set was used for our experiments (λex:
700–770 nm, λem > 780 nm). The liquid crystal tunable
filter (LCTF) was programmed to acquire image cubes
from λ = 780 nm-860 nm with an increment of 10 nm per
image. The camera was set to 150 ms (whole body image),
15 ms (liver), 500 ms (spleen), 7000 ms (kidney), 10 ms
(duodenum), 500 ms (colon), 1000 ms (brain), 1000 ms
(tibia bones), 200 ms (heart) and 1000 ms (blood) expos-
ure times. Fluorescence intensity measurements were per-
formed using ImageJ NIH (National Institutes of Health)
software.
Conjugation of tumor-targeting ligands to the NIR
fluorescent P(EF-PLLA) nanoparticles
Anti-CEA was covalently conjugated to the nanoparti-
cles through carbodiimide activation of the carboxylate
groups on the particle surface [6]. Briefly, EDC (1 mg)
and Sulfo-NHS (1 mg) were dissolves separately in 1 mL
0.1 M MES containing 0.5 M NaCl. The EDC solution
(10 μL, 1 mg/mL) was then added to an aqueous anti-
CEA solution (62.5 μL, 0.25 mg) followed by the addition
of the Sulfo-NHS solution (25 μL, 1 mg/mL). The mixture
was shaken at room temperature for 15 min, and then
the NIR fluorescent nanoparticle dispersion was added
(2.5 mg in 1 mL PBS). The mixture was shaken for an
additional 90 min. The obtained anti-CEA-conjugated
fluorescent nanoparticles were then washed from excess
reagents by dilution and filtration through a 30-kDa filtra-
tion tube (VS2021 VIVA SPIN) at 1000 rpm (CentrifugeCN-2200 MRC) for 2 min, repeated three times. Anti-
rabbit IgG was conjugated to the NIR fluorescent nano-
particles through a similar procedure. The concentration
of bound anti-CEA and anti-rabbit IgG (1.9 ± 0.2 μg/mg
nanoparticles) was determined using a mouse IgG ELISA
kit (Biotest, Israel).
Optical detection of human colon tumor with the
non-conjugated and bio-conjugated NIR fluorescent
P(EF-PLLA) in a chicken embryo chorioallantoic
membrane (CAM)
Human colorectal adenocarcinoma LS174t and SW480
cell lines were used for each of the experiments and main-
tained as mentioned above. Tumor cells were grafted on
CAM according to the literature [38]. Briefly, fertile
chicken eggs obtained from a commercial supplier were
incubated at 37°C at 60–70% humidity in a forced-draft
incubator. On day 3 of incubation, an artificial air sac was
formed, allowing the CAM to drop. After 8 days of incu-
bation, a window was opened in the shell and the CAM
was exposed. Tumor cells were collected by trypsinization,
washed with culture medium and pelleted by gentle cen-
trifugation. Following removal of the medium, 5×106 cells
were resuspended in 30 μL ice-cold Matrigel and inocu-
lated on the CAM at the site of the blood vessels. Eggs
were then sealed and returned to incubation. On day 6
post-grafting, day 14 of incubation, the tumor diameter
ranged from 3 to 5 mm with visible neoangiogenesis.
Chicken embryos with 6-days-old human adenocarcinoma
tumors (LS174t and SW480 cancer cell lines) implanted
on the CAM were treated with the non-conjugated, anti-
CEA-conjugated and anti-rabbit IgG-conjugated NIR
fluorescent P(EF-PLLA) nanoparticles (40 μL, 2 mg/mL).
Additionally, non-pathological CAM treated with nano-
particles and untreated tumors served as control groups.
After 40 minutes, the nanoparticle dispersions were re-
moved and the tumors were washed with PBS. Then, the
tumors and the non-pathological CAM were removed
from the eggs, washed again with PBS and spread on a
mat black background for observation using a Maestro II
in vivo imaging system (Cambridge Research & Instru-
mentation, Inc., Woburn, MA). A NIR excitation/emission
filter set was used for the experiments (λex: 710–760 nm,
λem > 750 nm). The Liquid Crystal Tunable Filter (LCTF)
was programmed to acquire image cubes from λ = 790 nm
to 860 nm with an increment of 10 nm per image. Fluores-
cence intensity measurements were calculated as average
intensity over the tumor surface area, using ImageJ software.
Optical detection of human colon tumor with the
non-conjugated and bio-conjugated NIR fluorescent
P(EF-PLLA) in a mouse model
Experiments were performed according to the protocols
of the Israeli National Council for Animal Experiments
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2 × 106 LS174t cells) were injected into the mouse intestinal
wall. 2 weeks later the nude mice were anaesthetized
and treated with the bio-conjugated NIR fluorescent P
(EF-PLLA) nanoparticles (0.1%, 200 μL), through the
anus, using the guidance of a mini-colonoscope. 20 min
later each colon was washed with PBS (5 × 1 mL) and
mice were allowed to recover for 4 h. The mice were sacri-
ficed and the colons were removed. Each colon was spread
on a solid surface and imaging was performed using the
Odysey Infrared Imaging System (Li-Cor Biosciences,
Lincoln, NE, USA) with excitation wavelength of 780 nm
and emission wavelength of 800 nm.
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